

## ASX Announcement

15 January 2025

### OncoSil Medical Appoints Lel Smits as Non-Executive Director

**Sydney, Australia – 15 January 2025:** Pancreatic cancer treatment device company **OncoSil Medical Limited (ASX:OSL)** (“OncoSil” or “the Company”) is pleased to announce the appointment of Ms. Lel Smits as a Non-Executive Director to the Board of OncoSil Medical, effective immediately. Ms. Smits brings a wealth of expertise in governance, strategy, risk oversight, and corporate communications, with a distinguished career advising over 500 ASX-listed management teams and Boards.

Ms. Smits is an award-winning entrepreneur and director, recognised as Director of the Year by Women in Finance in both 2024 and 2022. Since 2021, she has served as a Director on the Board of Australian Shareholders' Association. Her extensive career began as a finance journalist, including roles as a foreign correspondent in New York, reporting from inside the New York Stock Exchange on Wall Street.

With deep experience in the financial markets and corporate affairs, Ms. Smits has contributed significantly to entrepreneurial ventures and Boards, enhancing their governance and strategic direction. She holds formal qualifications including a Master of Arts in Journalism from the University of Technology, Sydney (UTS), a Diploma of Investor Relations from the Australasian Investor Relations Association (AIRA) and is a graduate of the Australian Institute of Company Directors' (AICD) Company Directors Course.

**Nigel Lange, CEO & Managing Director of OncoSil Medical, said:**

*"We are delighted to welcome Lel to the OncoSil Board. Her extensive experience across governance, strategy, and corporate affairs will be invaluable as we continue to advance our mission of delivering innovative treatments to patients globally. Her strategic insights and leadership in investor relations will undoubtedly strengthen our efforts to create value for all stakeholders."*

**Lel Smits stated:**

*"I am honoured to join the Board of OncoSil Medical at such a pivotal time for the company. OncoSil's commitment to improving patient outcomes aligns with my passion for fostering innovation and governance excellence. I look forward to utilising my extensive experience across corporate communications, media and investor relations to contribute to the company's strategic objectives and supporting its growth journey."*

The Board of OncoSil Medical warmly welcomes Ms. Smits and looks forward to her contributions in supporting the company's vision and objectives.

## Authorisation & Additional Information

This announcement was authorised by the Chairman of OncoSil Medical Limited.

### For further information, please contact:

<b>Mr. Nigel Lange</b> CEO & Managing Director E: <a href="mailto:nigel.lange@oncosil.com">nigel.lange@oncosil.com</a> T: +49 30 300 149 3043	<b>Mr. Christian Dal Cin</b> CFO & Company Secretary E: <a href="mailto:c.dalcin@acclime.com">c.dalcin@acclime.com</a> T: +61 3 9824 5254	<b>Ms. Julia Maguire</b> <b>The Capital Network</b> Media and Investor Enquiries E: <a href="mailto:julia@thecapitalnetwork.com.au">julia@thecapitalnetwork.com.au</a> T: +61 2 8999 3699
--	--	---

### About OncoSil Medical

OncoSil Medical Limited (ASX:OSL) has developed a cancer treatment device, the OncoSil™ brachytherapy device, which is a critical component of a revolutionary brachytherapy treatment for locally advanced unresectable pancreatic cancer. This type of cancer is the 12<sup>th</sup> most common cancer in men and the 11<sup>th</sup> most common cancer in women across the globe, with some 500,000 new cases of pancreatic cancer detected every year. With pancreatic cancer typically diagnosed at a later stage, it has a poor prognosis for long-term survival<sup>1</sup>.

The OncoSil™ device delivers a targeted intratumoural placement of Phosphorous-32 (<sup>32</sup>P) in the treatment of locally advanced unresectable pancreatic cancer. This occurs via injection directly into a patient's pancreatic tumours under endoscopic ultrasound guidance and takes place in combination with gemcitabine-based chemotherapy.

The OncoSil™ device that has already received breakthrough device designation in the European Union, United Kingdom and United States for the treatment of locally advanced unresectable pancreatic cancer in combination with chemotherapy. CE Marking has additionally been granted for the OncoSil™ device, which can be marketed in the European Union, United Kingdom.

While clinical trials involving the OncoSil™ device continue to occur, the Company is simultaneously moving to commercialise this unique medical technology. It is currently approved for sale in 30+ countries including European Union, United Kingdom, Türkiye and Israel, with initial commercial pancreatic cancer treatments using the device already undertaken in Spain, Italy and Israel.

To learn more, please visit: [www.oncosil.com/](http://www.oncosil.com/)

**References:** 1. <https://www.wcrf.org/cancer-trends/pancreatic-cancer-statistics/>